1
|
Jackson A, Pathak R, deSouza NM, Liu Y, Jacobs BKM, Litiere S, Urbanowicz-Nijaki M, Julie C, Chiti A, Theysohn J, Ayuso JR, Stroobants S, Waterton JC. MRI Apparent Diffusion Coefficient (ADC) as a Biomarker of Tumour Response: Imaging-Pathology Correlation in Patients with Hepatic Metastases from Colorectal Cancer (EORTC 1423). Cancers (Basel) 2023; 15:3580. [PMID: 37509240 PMCID: PMC10377224 DOI: 10.3390/cancers15143580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2023] [Revised: 06/29/2023] [Accepted: 06/30/2023] [Indexed: 07/30/2023] Open
Abstract
Background: Tumour apparent diffusion coefficient (ADC) from diffusion-weighted magnetic resonance imaging (MRI) is a putative pharmacodynamic/response biomarker but the relationship between drug-induced effects on the ADC and on the underlying pathology has not been adequately defined. Hypothesis: Changes in ADC during early chemotherapy reflect underlying histological markers of tumour response as measured by tumour regression grade (TRG). Methods: Twenty-six patients were enrolled in the study. Baseline, 14 days, and pre-surgery MRI were performed per study protocol. Surgical resection was performed in 23 of the enrolled patients; imaging-pathological correlation was obtained from 39 lesions from 21 patients. Results: There was no evidence of correlation between TRG and ADC changes at day 14 (study primary endpoint), and no significant correlation with other ADC metrics. In scans acquired one week prior to surgery, there was no significant correlation between ADC metrics and percentage of viable tumour, percentage necrosis, percentage fibrosis, or Ki67 index. Conclusions: Our hypothesis was not supported by the data. The lack of meaningful correlation between change in ADC and TRG is a robust finding which is not explained by variability or small sample size. Change in ADC is not a proxy for TRG in metastatic colorectal cancer.
Collapse
Affiliation(s)
- Alan Jackson
- Centre for Imaging Sciences, University of Manchester, Manchester M20 4GJ, UK
| | - Ryan Pathak
- Centre for Imaging Sciences, University of Manchester, Manchester M20 4GJ, UK
| | - Nandita M deSouza
- CRUK Cancer Imaging Centre, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, London SW7 3RP, UK
| | - Yan Liu
- European Organisation for Research and Treatment of Cancer, 1200 Brussels, Belgium
| | - Bart K M Jacobs
- European Organisation for Research and Treatment of Cancer, 1200 Brussels, Belgium
| | - Saskia Litiere
- European Organisation for Research and Treatment of Cancer, 1200 Brussels, Belgium
| | | | - Catherine Julie
- EA 4340 BECCOH, UVSQ, Universite Paris-Saclay, 92104 Boulogne-Billancourt, France
- Department of Pathology, APHP-Hopital Ambroise Pare, 92100 Boulogne-Billancourt, France
| | - Arturo Chiti
- Nuclear Medicine Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy
- Department of Bio-Medical Sciences, Humanitas University, 20072 Milan, Italy
| | - Jens Theysohn
- Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany
| | - Juan R Ayuso
- Radiology Department-CDI, Hospital Clinic Universitari de Barcelona, 08036 Barcelona, Spain
| | - Sigrid Stroobants
- Molecular Imaging and Radiology, University of Antwerp, 2000 Antwerp, Belgium
| | - John C Waterton
- Centre for Imaging Sciences, University of Manchester, Manchester M20 4GJ, UK
| |
Collapse
|
2
|
Malyarenko D, Amouzandeh G, Pickup S, Zhou R, Manning HC, Gammon ST, Shoghi KI, Quirk JD, Sriram R, Larson P, Lewis MT, Pautler RG, Kinahan PE, Muzi M, Chenevert TL. Evaluation of Apparent Diffusion Coefficient Repeatability and Reproducibility for Preclinical MRIs Using Standardized Procedures and a Diffusion-Weighted Imaging Phantom. Tomography 2023; 9:375-386. [PMID: 36828382 PMCID: PMC9964373 DOI: 10.3390/tomography9010030] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2022] [Revised: 01/31/2023] [Accepted: 02/02/2023] [Indexed: 02/10/2023] Open
Abstract
Relevant to co-clinical trials, the goal of this work was to assess repeatability, reproducibility, and bias of the apparent diffusion coefficient (ADC) for preclinical MRIs using standardized procedures for comparison to performance of clinical MRIs. A temperature-controlled phantom provided an absolute reference standard to measure spatial uniformity of these performance metrics. Seven institutions participated in the study, wherein diffusion-weighted imaging (DWI) data were acquired over multiple days on 10 preclinical scanners, from 3 vendors, at 6 field strengths. Centralized versus site-based analysis was compared to illustrate incremental variance due to processing workflow. At magnet isocenter, short-term (intra-exam) and long-term (multiday) repeatability were excellent at within-system coefficient of variance, wCV [±CI] = 0.73% [0.54%, 1.12%] and 1.26% [0.94%, 1.89%], respectively. The cross-system reproducibility coefficient, RDC [±CI] = 0.188 [0.129, 0.343] µm2/ms, corresponded to 17% [12%, 31%] relative to the reference standard. Absolute bias at isocenter was low (within 4%) for 8 of 10 systems, whereas two high-bias (>10%) scanners were primary contributors to the relatively high RDC. Significant additional variance (>2%) due to site-specific analysis was observed for 2 of 10 systems. Base-level technical bias, repeatability, reproducibility, and spatial uniformity patterns were consistent with human MRIs (scaled for bore size). Well-calibrated preclinical MRI systems are capable of highly repeatable and reproducible ADC measurements.
Collapse
Affiliation(s)
- Dariya Malyarenko
- Department of Radiology, University of Michigan, Ann Arbor, MI 48109, USA
| | - Ghoncheh Amouzandeh
- Department of Radiology, University of Michigan, Ann Arbor, MI 48109, USA
- Neuro42, Inc., San Francisco, CA 94105, USA
| | - Stephen Pickup
- Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Rong Zhou
- Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Henry Charles Manning
- Department of Cancer Systems Imaging, The University of Texas MDACC, Houston, TX 77030, USA
| | - Seth T. Gammon
- Department of Cancer Systems Imaging, The University of Texas MDACC, Houston, TX 77030, USA
| | - Kooresh I. Shoghi
- Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA
| | - James D. Quirk
- Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA
| | - Renuka Sriram
- UCSF Department of Radiology & Biomedical Imaging, San Francisco, CA 94158, USA
| | - Peder Larson
- UCSF Department of Radiology & Biomedical Imaging, San Francisco, CA 94158, USA
| | | | | | - Paul E. Kinahan
- Department of Radiology, University of Washington, Seattle, WA 98195, USA
| | - Mark Muzi
- Department of Radiology, University of Washington, Seattle, WA 98195, USA
| | | |
Collapse
|
3
|
Paquier Z, Chao SL, Bregni G, Sanchez AV, Guiot T, Dhont J, Gulyban A, Levillain H, Sclafani F, Reynaert N, Bali MA. Pre-trial quality assurance of diffusion-weighted MRI for radiomic analysis and the role of harmonisation. Phys Med 2022; 103:138-146. [DOI: 10.1016/j.ejmp.2022.10.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/16/2022] [Revised: 09/30/2022] [Accepted: 10/08/2022] [Indexed: 11/17/2022] Open
|
4
|
Teh I, Romero R. WA, Boyle J, Coll‐Font J, Dall'Armellina E, Ennis DB, Ferreira PF, Kalra P, Kolipaka A, Kozerke S, Lohr D, Mongeon F, Moulin K, Nguyen C, Nielles‐Vallespin S, Raterman B, Schreiber LM, Scott AD, Sosnovik DE, Stoeck CT, Tous C, Tunnicliffe EM, Weng AM, Croisille P, Viallon M, Schneider JE. Validation of cardiac diffusion tensor imaging sequences: A multicentre test-retest phantom study. NMR IN BIOMEDICINE 2022; 35:e4685. [PMID: 34967060 PMCID: PMC9285553 DOI: 10.1002/nbm.4685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 05/24/2021] [Revised: 11/19/2021] [Accepted: 12/24/2021] [Indexed: 05/23/2023]
Abstract
Cardiac diffusion tensor imaging (DTI) is an emerging technique for the in vivo characterisation of myocardial microstructure, and there is a growing need for its validation and standardisation. We sought to establish the accuracy, precision, repeatability and reproducibility of state-of-the-art pulse sequences for cardiac DTI among 10 centres internationally. Phantoms comprising 0%-20% polyvinylpyrrolidone (PVP) were scanned with DTI using a product pulsed gradient spin echo (PGSE; N = 10 sites) sequence, and a custom motion-compensated spin echo (SE; N = 5) or stimulated echo acquisition mode (STEAM; N = 5) sequence suitable for cardiac DTI in vivo. A second identical scan was performed 1-9 days later, and the data were analysed centrally. The average mean diffusivities (MDs) in 0% PVP were (1.124, 1.130, 1.113) x 10-3 mm2 /s for PGSE, SE and STEAM, respectively, and accurate to within 1.5% of reference data from the literature. The coefficients of variation in MDs across sites were 2.6%, 3.1% and 2.1% for PGSE, SE and STEAM, respectively, and were similar to previous studies using only PGSE. Reproducibility in MD was excellent, with mean differences in PGSE, SE and STEAM of (0.3 ± 2.3, 0.24 ± 0.95, 0.52 ± 0.58) x 10-5 mm2 /s (mean ± 1.96 SD). We show that custom sequences for cardiac DTI provide accurate, precise, repeatable and reproducible measurements. Further work in anisotropic and/or deforming phantoms is warranted.
Collapse
Affiliation(s)
- Irvin Teh
- Leeds Institute of Cardiovascular and Metabolic MedicineUniversity of LeedsLeedsUK
| | - William A. Romero R.
- Univ Lyon, INSA‐Lyon, Université Claude Bernard Lyon 1UJM‐Saint Etienne, CNRS, Inserm, CREATIS UMR 5220, U1294, F‐42023Saint EtienneFrance
| | - Jordan Boyle
- School of Mechanical EngineeringUniversity of LeedsLeedsUK
| | - Jaume Coll‐Font
- Cardiovascular Research Center and A. A. Martinos Center for Biomedical ImagingMassachusetts General Hospital and Harvard Medical SchoolBostonMassachusettsUSA
| | - Erica Dall'Armellina
- Leeds Institute of Cardiovascular and Metabolic MedicineUniversity of LeedsLeedsUK
| | - Daniel B. Ennis
- Division of RadiologyVA Palo Alto Health Care SystemPalo AltoCaliforniaUSA
- Department of RadiologyStanford UniversityStanfordCaliforniaUSA
| | - Pedro F. Ferreira
- Cardiovascular Magnetic Resonance UnitThe Royal Brompton and Harefield NHS Foundation TrustLondonUK
- National Heart and Lung InstituteImperial College LondonLondonUK
| | - Prateek Kalra
- Department of RadiologyThe Ohio State University Wexner Medical CenterColumbusOhioUSA
| | - Arunark Kolipaka
- Department of RadiologyThe Ohio State University Wexner Medical CenterColumbusOhioUSA
| | - Sebastian Kozerke
- Institute for Biomedical EngineeringUniversity and ETH ZurichZurichSwitzerland
| | - David Lohr
- Department of Cardiovascular ImagingComprehensive Heart Failure CenterWürzburgGermany
| | | | - Kévin Moulin
- Department of RadiologyStanford UniversityStanfordCaliforniaUSA
| | - Christopher Nguyen
- Cardiovascular Research Center and A. A. Martinos Center for Biomedical ImagingMassachusetts General Hospital and Harvard Medical SchoolBostonMassachusettsUSA
| | - Sonia Nielles‐Vallespin
- Cardiovascular Magnetic Resonance UnitThe Royal Brompton and Harefield NHS Foundation TrustLondonUK
- National Heart and Lung InstituteImperial College LondonLondonUK
| | - Brian Raterman
- Department of RadiologyThe Ohio State University Wexner Medical CenterColumbusOhioUSA
| | - Laura M. Schreiber
- Department of Cardiovascular ImagingComprehensive Heart Failure CenterWürzburgGermany
| | - Andrew D. Scott
- Cardiovascular Magnetic Resonance UnitThe Royal Brompton and Harefield NHS Foundation TrustLondonUK
- National Heart and Lung InstituteImperial College LondonLondonUK
| | - David E. Sosnovik
- Cardiovascular Research Center and A. A. Martinos Center for Biomedical ImagingMassachusetts General Hospital and Harvard Medical SchoolBostonMassachusettsUSA
| | - Christian T. Stoeck
- Institute for Biomedical EngineeringUniversity and ETH ZurichZurichSwitzerland
| | - Cyril Tous
- Department of Radiology, Radiation‐Oncology and Nuclear Medicine and Institute of Biomedical EngineeringUniversité de MontréalMontréalCanada
| | - Elizabeth M. Tunnicliffe
- Radcliffe Department of MedicineUniversity of OxfordOxfordUK
- Oxford NIHR Biomedical Research CentreOxfordUK
| | - Andreas M. Weng
- Department of Diagnostic and Interventional RadiologyUniversity Hospital WürzburgWürzburgGermany
| | - Pierre Croisille
- Univ Lyon, INSA‐Lyon, Université Claude Bernard Lyon 1UJM‐Saint Etienne, CNRS, Inserm, CREATIS UMR 5220, U1294, F‐42023Saint EtienneFrance
| | - Magalie Viallon
- Univ Lyon, INSA‐Lyon, Université Claude Bernard Lyon 1UJM‐Saint Etienne, CNRS, Inserm, CREATIS UMR 5220, U1294, F‐42023Saint EtienneFrance
| | - Jürgen E. Schneider
- Leeds Institute of Cardiovascular and Metabolic MedicineUniversity of LeedsLeedsUK
| |
Collapse
|
5
|
Carr ME, Keenan KE, Rai R, Boss MA, Metcalfe P, Walker A, Holloway L. Conformance of a 3T Radiotherapy MRI Scanner to the QIBA Diffusion Profile. Med Phys 2022; 49:4508-4517. [PMID: 35365884 PMCID: PMC9543906 DOI: 10.1002/mp.15645] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2021] [Revised: 03/12/2022] [Accepted: 03/16/2022] [Indexed: 11/11/2022] Open
Abstract
Purpose To assess the technical performance of the apparent diffusion coefficient (ADC) on a dedicated 3T radiotherapy scanner, using a standardized phantom and sequences. Investigations into factors that could impact the technical performance of ADC in the clinic were also completed, including changing the slice‐encoded imaging direction and the reference sample ADC value. Methods ADC acquisitions were performed monthly on an isotropic diffusion phantom over 1 year. Measurements of ADC %bias, coefficients of variation for short‐/long‐term repeatability and precision (CVST/CVLT and CVP), and b‐value dependency (Depb) were calculated. The measurements were then assessed according to the Quantitative Imaging Biomarker Alliance (QIBA) Diffusion Profile specifications. Results The average of all measurements over the year was within Profile recommended ranges. This included when testing was performed in different imaging directions, and on samples that had different ADC reference values (0.4–1.1 μm2/ms). Results in the axial plane for the central water vial included a bias of +0.05%, CVST /CVLT/CVP = 0.1%/ 0.9%/0.4% and Depb = 0.4%. Conclusions The technical performance of ADC on a radiotherapy dedicated MRI scanner over the course of 12 months was considered conformant to the QIBA Profile. Quantifying these metrics and factors that may affect the performance is essential in progressing the use of ADC clinically: ensuring that the observed change of ADC in a tissue is due to a physiological response and not measurement variability.
Collapse
Affiliation(s)
- Madeline E Carr
- Centre for Medical and Radiation Physics, University of Wollongong, Wollongong, Australia.,Ingham Institute for Applied Medical Research, Liverpool, Australia.,Liverpool and Macarthur Cancer Therapy Centres, Sydney, Australia
| | - Kathryn E Keenan
- National Institute of Standards and Technology, Boulder, United States
| | - Robba Rai
- Ingham Institute for Applied Medical Research, Liverpool, Australia.,Liverpool and Macarthur Cancer Therapy Centres, Sydney, Australia.,Institute of Medical Physics, University of Sydney, Camperdown, Australia
| | - Michael A Boss
- American College of Radiology, Philadelphia, United States
| | - Peter Metcalfe
- Centre for Medical and Radiation Physics, University of Wollongong, Wollongong, Australia.,Ingham Institute for Applied Medical Research, Liverpool, Australia
| | - Amy Walker
- Centre for Medical and Radiation Physics, University of Wollongong, Wollongong, Australia.,Ingham Institute for Applied Medical Research, Liverpool, Australia.,Liverpool and Macarthur Cancer Therapy Centres, Sydney, Australia.,Institute of Medical Physics, University of Sydney, Camperdown, Australia
| | - Lois Holloway
- Centre for Medical and Radiation Physics, University of Wollongong, Wollongong, Australia.,Ingham Institute for Applied Medical Research, Liverpool, Australia.,Liverpool and Macarthur Cancer Therapy Centres, Sydney, Australia.,Institute of Medical Physics, University of Sydney, Camperdown, Australia.,South Western Sydney Clinical School, University of New South Wales, Liverpool, Australia
| |
Collapse
|
6
|
Duffton A, Kemp O, Devlin L, Hay L, McLoone P, Paterson C. Feasibility of DW-MRI analysis of salivary glands during head and neck radiotherapy. Tech Innov Patient Support Radiat Oncol 2021; 19:46-51. [PMID: 34527819 PMCID: PMC8430428 DOI: 10.1016/j.tipsro.2021.07.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2021] [Revised: 06/30/2021] [Accepted: 07/06/2021] [Indexed: 11/25/2022] Open
Abstract
INTRODUCTION With no effective treatment for xerostomia, there remains an unmet need to reduce radiation induced toxicity. Measuring physiological changes during RT in salivary glands using DW-MRI may predict which patients are most at risk of severe toxicity. This study evaluated the feasibility of measuring apparent diffusion coefficient (ADC) in the major salivary glands and describes the observed changes in volume and ADC during RT. METHODS Scans were acquired at baseline (MR_base) and after 10 fractions (MR_rpt). Sequences included T1 post contrast fat saturated (T1PCFS) and DW-MRI (5b values, 0-1000 s/mm2). Ipsilateral and contralateral parotid (iPG/cPG), submandibular (iSMG/cSMG) and sublingual glands (iSLG/cSLG) were delineated on T1PCFS, modified on b0 and copied to the ADC map. RESULTS 31 patients with intermediate/high risk squamous cell carcinoma (SCC) of the oropharynx were evaluated. On 124 scans, SMG and SLG delineations were successful on all; parotids were fully contoured in 90.7%. Baseline mean ADC were significantly different between each gland type (p < 0.0001). IPG and cPG volume decreased during treatment by 6.7% and 11.2%. ISMG, cSMG, iSLG and cSLG volume increased by 6.9, 0.9, 60.8 and 60.3% respectively. All structures showed an increase in mean_ADC values. For each gland the increase in ADC was statistically significant p < 0.0001. A smaller mean percentage increase in ADC was observed in the group experiencing a higher grade (2 or > ) of toxicity. CONCLUSION It is feasible to measure volume and ADC of the salivary glands prior to and during RT for HNC. Early data suggests a lower rise in ADC during treatment is associated with more severe late xerostomia.
Collapse
Affiliation(s)
- Aileen Duffton
- Department of Radiotherapy, The Beatson West of Scotland Cancer Centre, Glasgow G12 0YN, United Kingdom
| | - Olivia Kemp
- School of Medicine, Veterinary and Life Science, University of Glasgow, Glasgow, United Kingdom
| | - Lynsey Devlin
- Department of Radiotherapy, The Beatson West of Scotland Cancer Centre, Glasgow G12 0YN, United Kingdom
| | - Lisa Hay
- Department of Radiotherapy, The Beatson West of Scotland Cancer Centre, Glasgow G12 0YN, United Kingdom
| | - Philip McLoone
- Institute of Health & Wellbeing, University of Glasgow, Glasgow, United Kingdom
| | - Claire Paterson
- Department of Clinical Oncology, The Beatson West of Scotland Cancer Centre, Glasgow G12 0YN, United Kingdom
| |
Collapse
|
7
|
McGee KP, Hwang KP, Sullivan DC, Kurhanewicz J, Hu Y, Wang J, Li W, Debbins J, Paulson E, Olsen JR, Hua CH, Warner L, Ma D, Moros E, Tyagi N, Chung C. Magnetic resonance biomarkers in radiation oncology: The report of AAPM Task Group 294. Med Phys 2021; 48:e697-e732. [PMID: 33864283 PMCID: PMC8361924 DOI: 10.1002/mp.14884] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2020] [Revised: 03/24/2021] [Accepted: 03/28/2021] [Indexed: 12/16/2022] Open
Abstract
A magnetic resonance (MR) biologic marker (biomarker) is a measurable quantitative characteristic that is an indicator of normal biological and pathogenetic processes or a response to therapeutic intervention derived from the MR imaging process. There is significant potential for MR biomarkers to facilitate personalized approaches to cancer care through more precise disease targeting by quantifying normal versus pathologic tissue function as well as toxicity to both radiation and chemotherapy. Both of which have the potential to increase the therapeutic ratio and provide earlier, more accurate monitoring of treatment response. The ongoing integration of MR into routine clinical radiation therapy (RT) planning and the development of MR guided radiation therapy systems is providing new opportunities for MR biomarkers to personalize and improve clinical outcomes. Their appropriate use, however, must be based on knowledge of the physical origin of the biomarker signal, the relationship to the underlying biological processes, and their strengths and limitations. The purpose of this report is to provide an educational resource describing MR biomarkers, the techniques used to quantify them, their strengths and weakness within the context of their application to radiation oncology so as to ensure their appropriate use and application within this field.
Collapse
Affiliation(s)
- Kiaran P McGee
- Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
| | - Ken-Pin Hwang
- Department of Imaging Physics, Division of Diagnostic Imaging, MD Anderson Cancer Center, University of Texas, Houston, Texas, USA
| | - Daniel C Sullivan
- Department of Radiology, Duke University, Durham, North Carolina, USA
| | - John Kurhanewicz
- Department of Radiology, University of California, San Francisco, California, USA
| | - Yanle Hu
- Department of Radiation Oncology, Mayo Clinic, Scottsdale, Arizona, USA
| | - Jihong Wang
- Department of Radiation Oncology, MD Anderson Cancer Center, University of Texas, Houston, Texas, USA
| | - Wen Li
- Department of Radiation Oncology, University of Arizona, Tucson, Arizona, USA
| | - Josef Debbins
- Department of Radiology, Barrow Neurologic Institute, Phoenix, Arizona, USA
| | - Eric Paulson
- Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
| | - Jeffrey R Olsen
- Department of Radiation Oncology, University of Colorado Denver - Anschutz Medical Campus, Denver, Colorado, USA
| | - Chia-Ho Hua
- Department of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA
| | | | - Daniel Ma
- Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA
| | - Eduardo Moros
- Department of Radiation Oncology, Moffitt Cancer Center, Tampa, Florida, USA
| | - Neelam Tyagi
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Caroline Chung
- Department of Radiation Oncology, MD Anderson Cancer Center, University of Texas, Houston, Texas, USA
| |
Collapse
|
8
|
Boursianis T, Kalaitzakis G, Pappas E, Karantanas AH, Maris TG. MRI diffusion phantoms: ADC and relaxometric measurement comparisons between polyacrylamide and agarose gels. Eur J Radiol 2021; 139:109696. [PMID: 33865063 DOI: 10.1016/j.ejrad.2021.109696] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2020] [Revised: 03/30/2021] [Accepted: 04/05/2021] [Indexed: 10/21/2022]
Abstract
PURPOSE The aim of this study is to compare polyacrylamide and agarose gels, as components of a simple MRI phantom, for the measurements of Apparent Diffusion Coefficient (ADC), T1 and T2 relaxation times. MATERIALS AND METHODS Five (5) test tubes with polyacrylamide gels of different monomer concentrations and six (6) test tubes of different agarose gel concentrations were used as a phantom for ADC, T1 and T2 measurements, which were expressed as 2D color parametric maps, on a 1.5 T clinical MRI system. ADC and T2 maps were calculated utilizing a Weighted Linear (WL) regression fitting algorithm. T1 maps were calculated utilizing a standard non-linear fitting algorithm. RESULTS In agarose gels, ADC measurements are independent of the agarose concentration, whereas the T1 and T2 relaxation times decrease with increasing agarose concentration. On the contrary, in polyacrylamide gels, ADC measurements decrease quadratically while increasing the monomer concentration, whereas the T1 and T2 relaxation times reveal a linear decrease with increasing monomer concentration. CONCLUSION Polyacrylamide gels can serve as a better means for simulating ADC values, as compared with the agarose gels used in this study.
Collapse
Affiliation(s)
- T Boursianis
- Department of Medical Physics, University of Crete, Heraklion, Crete, Greece.
| | - G Kalaitzakis
- Department of Medical Physics, University of Crete, Heraklion, Crete, Greece.
| | - E Pappas
- Department of Biomedical Sciences, Radiology & Radiotherapy Sector, University of West Attica, Athens, Greece.
| | - A H Karantanas
- Department of Radiology, University of Crete, Heraklion, Crete, Greece; Computational BioMedicine Laboratory, Institute of Computer Science, Foundation for Research and Technology-Hellas (FORTH), Heraklion, Crete, Greece; Department of Medical Imaging, University Hosptital, Heraklion, Crete, Greece.
| | - T G Maris
- Department of Medical Physics, University of Crete, Heraklion, Crete, Greece; Computational BioMedicine Laboratory, Institute of Computer Science, Foundation for Research and Technology-Hellas (FORTH), Heraklion, Crete, Greece.
| |
Collapse
|
9
|
Jerome NP, Periquito JS. Analysis of Renal Diffusion-Weighted Imaging (DWI) Using Apparent Diffusion Coefficient (ADC) and Intravoxel Incoherent Motion (IVIM) Models. Methods Mol Biol 2021; 2216:611-635. [PMID: 33476027 DOI: 10.1007/978-1-0716-0978-1_37] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/19/2023]
Abstract
Analysis of renal diffusion-weighted imaging (DWI) data to derive markers of tissue properties requires careful consideration of the type, extent, and limitations of the acquired data. Alongside data quality and general suitability for quantitative analysis, choice of diffusion model, fitting algorithm, and processing steps can have consequences for the precision, accuracy, and reliability of derived diffusion parameters. Here we introduce and discuss important steps for diffusion-weighted image processing, and in particular give example analysis protocols and pseudo-code for analysis using the apparent diffusion coefficient (ADC) and intravoxel incoherent motion (IVIM) models. Following an overview of general principles, we provide details of optional steps, and steps for validation of results. Illustrative examples are provided, together with extensive notes discussing wider context of individual steps, and notes on potential pitfalls.This publication is based upon work from the COST Action PARENCHIMA, a community-driven network funded by the European Cooperation in Science and Technology (COST) program of the European Union, which aims to improve the reproducibility and standardization of renal MRI biomarkers. This analysis protocol chapter is complemented by two separate chapters describing the basic concepts and experimental procedure.
Collapse
Affiliation(s)
- Neil Peter Jerome
- Institute for Circulation and Diagnostic Imaging, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
- Department of Radiology and Nuclear Medicine, St. Olav's University Hospital, Trondheim, Norway.
| | - João S Periquito
- Berlin Ultrahigh Field Facility (B.U.F.F.), Max Delbrück Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany
| |
Collapse
|
10
|
Apparent diffusion coefficient measurements on a novel diffusion weighted MRI phantom utilizing EPI and HASTE sequences. Phys Med 2020; 73:179-189. [DOI: 10.1016/j.ejmp.2020.04.024] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/21/2020] [Revised: 04/17/2020] [Accepted: 04/25/2020] [Indexed: 11/21/2022] Open
|
11
|
Mikayama R, Yabuuchi H, Matsumoto R, Kobayashi K, Yamashita Y, Kimura M, Kamitani T, Sagiyama K, Yamasaki Y. Development of a new phantom simulating extracellular space of tumor cell growth and cell edema for diffusion-weighted magnetic resonance imaging. MAGNETIC RESONANCE MATERIALS IN PHYSICS BIOLOGY AND MEDICINE 2020; 33:507-513. [DOI: 10.1007/s10334-019-00823-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/31/2019] [Revised: 12/07/2019] [Accepted: 12/19/2019] [Indexed: 12/30/2022]
|
12
|
Waterton JC, Hines CDG, Hockings PD, Laitinen I, Ziemian S, Campbell S, Gottschalk M, Green C, Haase M, Hassemer K, Juretschke HP, Koehler S, Lloyd W, Luo Y, Mahmutovic Persson I, O'Connor JPB, Olsson LE, Pindoria K, Schneider JE, Sourbron S, Steinmann D, Strobel K, Tadimalla S, Teh I, Veltien A, Zhang X, Schütz G. Repeatability and reproducibility of longitudinal relaxation rate in 12 small-animal MRI systems. Magn Reson Imaging 2019; 59:121-129. [PMID: 30872166 PMCID: PMC6477178 DOI: 10.1016/j.mri.2019.03.008] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2018] [Revised: 01/29/2019] [Accepted: 03/08/2019] [Indexed: 12/13/2022]
Abstract
BACKGROUND Many translational MR biomarkers derive from measurements of the water proton longitudinal relaxation rate R1, but evidence for between-site reproducibility of R1 in small-animal MRI is lacking. OBJECTIVE To assess R1 repeatability and multi-site reproducibility in phantoms for preclinical MRI. METHODS R1 was measured by saturation recovery in 2% agarose phantoms with five nickel chloride concentrations in 12 magnets at 5 field strengths in 11 centres on two different occasions within 1-13 days. R1 was analysed in three different regions of interest, giving 360 measurements in total. Root-mean-square repeatability and reproducibility coefficients of variation (CoV) were calculated. Propagation of reproducibility errors into 21 translational MR measurements and biomarkers was estimated. Relaxivities were calculated. Dynamic signal stability was also measured. RESULTS CoV for day-to-day repeatability (N = 180 regions of interest) was 2.34% and for between-centre reproducibility (N = 9 centres) was 1.43%. Mostly, these do not propagate to biologically significant between-centre error, although a few R1-based MR biomarkers were found to be quite sensitive even to such small errors in R1, notably in myocardial fibrosis, in white matter, and in oxygen-enhanced MRI. The relaxivity of aqueous Ni2+ in 2% agarose varied between 0.66 s-1 mM-1 at 3 T and 0.94 s-1 mM-1 at 11.7T. INTERPRETATION While several factors affect the reproducibility of R1-based MR biomarkers measured preclinically, between-centre propagation of errors arising from intrinsic equipment irreproducibility should in most cases be small. However, in a few specific cases exceptional efforts might be required to ensure R1-reproducibility.
Collapse
Affiliation(s)
- John C Waterton
- Bioxydyn Ltd, Manchester Science Park, Rutherford House, Pencroft Way, MANCHESTER M15 6SZ, United Kingdom; Centre for Imaging Sciences, Division of Informatics Imaging & Data Sciences, School of Health Sciences, Faculty of Biology Medicine & Health, University of Manchester, Manchester Academic Health Sciences Centre, MANCHESTER M13 9PL, United Kingdom.
| | | | - Paul D Hockings
- Antaros Medical, BioVenture Hub, 43183 Mölndal, Sweden; MedTech West, Chalmers University of Technology, Gothenburg, Sweden.
| | - Iina Laitinen
- Sanofi-Aventis Deutschland GmbH, R&D TIM - Bioimaging Germany, Industriepark Höchst, D-65926 Frankfurt am Main, Germany.
| | - Sabina Ziemian
- Bayer AG, Research and Development, Pharmaceuticals, MR and CT Contrast Media Research, Müllerstraße 178, D-13353 Berlin, Germany.
| | - Simon Campbell
- In-Vivo Bioimaging UK, RD Platform Technology & Science, GSK Medicines Research Centre, Gunnels Wood Road, STEVENAGE, Hertfordshire, SG1 2NY, United Kingdom.
| | - Michael Gottschalk
- Lund University BioImaging Center, Klinikgatan 32, SE-222-42 Lund, Sweden.
| | - Claudia Green
- Bayer AG, Research and Development, Pharmaceuticals, MR and CT Contrast Media Research, Müllerstraße 178, D-13353 Berlin, Germany.
| | - Michael Haase
- In-Vivo Bioimaging UK, RD Platform Technology & Science, GSK Medicines Research Centre, Gunnels Wood Road, STEVENAGE, Hertfordshire, SG1 2NY, United Kingdom.
| | - Katja Hassemer
- Sanofi-Aventis Deutschland GmbH, R&D TIM - Bioimaging Germany, Industriepark Höchst, D-65926 Frankfurt am Main, Germany.
| | - Hans-Paul Juretschke
- Sanofi-Aventis Deutschland GmbH, R&D TIM - Bioimaging Germany, Industriepark Höchst, D-65926 Frankfurt am Main, Germany
| | - Sascha Koehler
- Bruker BioSpin MRI GmbH, Rudolf-Plank-Straße 23, D-76275 Ettlingen, Germany.
| | - William Lloyd
- Centre for Imaging Sciences, Division of Informatics Imaging & Data Sciences, School of Health Sciences, Faculty of Biology Medicine & Health, University of Manchester, Manchester Academic Health Sciences Centre, MANCHESTER M13 9PL, United Kingdom.
| | - Yanping Luo
- iSAT Discovery, Abbvie, 1 North Waukegan Road, North Chicago, IL, 60064-1802, United States of America.
| | - Irma Mahmutovic Persson
- Department of Translational Sciences, Medical Radiation Physics, Lund University, Skåne University Hospital, SE-205 02 Malmö, Sweden.
| | - James P B O'Connor
- Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology Medicine & Health, University of Manchester, Manchester Academic Health Sciences Centre, MANCHESTER M20 4BX, United Kingdom. james.o'
| | - Lars E Olsson
- Department of Translational Sciences, Medical Radiation Physics, Lund University, Skåne University Hospital, SE-205 02 Malmö, Sweden.
| | - Kashmira Pindoria
- In-Vivo Bioimaging UK, RD Platform Technology & Science, GSK Medicines Research Centre, Gunnels Wood Road, STEVENAGE, Hertfordshire, SG1 2NY, United Kingdom.
| | - Jurgen E Schneider
- Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds LS2 9JT, United Kingdom.
| | - Steven Sourbron
- Leeds Imaging Biomarkers Group, Department of Biomedical Imaging Sciences, University of Leeds, LIGHT Labs, Clarendon Way, LEEDS LS2 9JT, United Kingdom.
| | - Denise Steinmann
- Sanofi-Aventis Deutschland GmbH, R&D TIM - Bioimaging Germany, Industriepark Höchst, D-65926 Frankfurt am Main, Germany.
| | - Klaus Strobel
- Bruker BioSpin MRI GmbH, Rudolf-Plank-Straße 23, D-76275 Ettlingen, Germany.
| | - Sirisha Tadimalla
- Leeds Imaging Biomarkers Group, Department of Biomedical Imaging Sciences, University of Leeds, LIGHT Labs, Clarendon Way, LEEDS LS2 9JT, United Kingdom.
| | - Irvin Teh
- Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds LS2 9JT, United Kingdom.
| | - Andor Veltien
- Radboud university medical center, Radiology (766), P.O.Box 9101, 6500, HB, Nijmegen, the Netherlands.
| | - Xiaomeng Zhang
- iSAT Discovery, Abbvie, 1 North Waukegan Road, North Chicago, IL, 60064-1802, United States of America.
| | - Gunnar Schütz
- Bayer AG, Research and Development, Pharmaceuticals, MR and CT Contrast Media Research, Müllerstraße 178, D-13353 Berlin, Germany.
| |
Collapse
|
13
|
Tao AT, Shu Y, Tan ET, Trzasko JD, Tao S, Reid R, Weavers P, Huston J, Bernstein MA. Improving apparent diffusion coefficient accuracy on a compact 3T MRI scanner using gradient nonlinearity correction. J Magn Reson Imaging 2018; 48:1498-1507. [PMID: 30255963 PMCID: PMC6263730 DOI: 10.1002/jmri.26201] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2018] [Accepted: 05/08/2018] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND Gradient nonlinearity (GNL) leads to biased apparent diffusion coefficients (ADCs) in diffusion-weighted imaging. A gradient nonlinearity correction (GNLC) method has been developed for whole body systems, but is yet to be tested for the new compact 3T (C3T) scanner, which exhibits more complex GNL due to its asymmetrical design. PURPOSE To assess the improvement of ADC quantification with GNLC for the C3T scanner. STUDY TYPE Phantom measurements and retrospective analysis of patient data. PHANTOM/SUBJECTS A diffusion quality control phantom with vials containing 0-30% polyvinylpyrrolidone in water was used. For in vivo data, 12 patient exams were analyzed (median age, 33). FIELD STRENGTH/SEQUENCE Imaging was performed on the C3T and two commercial 3T scanners. A clinical DWI (repetition time [TR] = 10,000 msec, echo time [TE] = minimum, b = 1000 s/mm2 ) sequence was used for phantom imaging and 10 patient cases and a clinical DTI (TR = 6000-10,000 msec, TE = minimum, b = 1000 s/mm2 ) sequence was used for two patient cases. ASSESSMENT The 0% vial was measured along three orthogonal axes, and at two different temperatures. The ADC for each concentration was compared between the C3T and two whole-body scanners. Cerebrospinal fluid and white matter ADCs were quantified for each patient and compared to values in literature. STATISTICAL TESTS Paired t-test and two-way analysis of variance (ANOVA). RESULTS For all PVP concentrations, the corrected ADC was within 2.5% of the reference ADC. On average, the ADC of cerebrospinal fluid and white matter post-GNLC were within 1% and 6%, respectively, of values reported in the literature and were significantly different from the uncorrected data (P < 0.05). DATA CONCLUSION This study demonstrated that GNL effects were more severe for the C3T due to the asymmetric gradient design, but our implementation of a GNLC compensated for these effects, resulting in ADC values that are in good agreement with values from the literature. LEVEL OF EVIDENCE 4 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2018;48:1498-1507.
Collapse
Affiliation(s)
- Ashley T. Tao
- Department of Radiology, Mayo Clinic, Rochester, MN, USA
| | - Yunhong Shu
- Department of Radiology, Mayo Clinic, Rochester, MN, USA
| | - Ek T. Tan
- GE Global Research, Niskayuna, NY, USA
| | | | - Shengzhen Tao
- Department of Radiology, Mayo Clinic, Rochester, MN, USA
| | - Robert Reid
- Department of Information Technology, Mayo Clinic, Rochester, MN, USA
| | - Paul Weavers
- Department of Radiology, Mayo Clinic, Rochester, MN, USA
| | - John Huston
- Department of Radiology, Mayo Clinic, Rochester, MN, USA
| | | |
Collapse
|
14
|
Shukla-Dave A, Obuchowski NA, Chenevert TL, Jambawalikar S, Schwartz LH, Malyarenko D, Huang W, Noworolski SM, Young RJ, Shiroishi MS, Kim H, Coolens C, Laue H, Chung C, Rosen M, Boss M, Jackson EF. Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE-MRI derived biomarkers in multicenter oncology trials. J Magn Reson Imaging 2018; 49:e101-e121. [PMID: 30451345 DOI: 10.1002/jmri.26518] [Citation(s) in RCA: 219] [Impact Index Per Article: 36.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2018] [Revised: 09/06/2018] [Accepted: 09/06/2018] [Indexed: 12/14/2022] Open
Abstract
Physiological properties of tumors can be measured both in vivo and noninvasively by diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging. Although these techniques have been used for more than two decades to study tumor diffusion, perfusion, and/or permeability, the methods and studies on how to reduce measurement error and bias in the derived imaging metrics is still lacking in the literature. This is of paramount importance because the objective is to translate these quantitative imaging biomarkers (QIBs) into clinical trials, and ultimately in clinical practice. Standardization of the image acquisition using appropriate phantoms is the first step from a technical performance standpoint. The next step is to assess whether the imaging metrics have clinical value and meet the requirements for being a QIB as defined by the Radiological Society of North America's Quantitative Imaging Biomarkers Alliance (QIBA). The goal and mission of QIBA and the National Cancer Institute Quantitative Imaging Network (QIN) initiatives are to provide technical performance standards (QIBA profiles) and QIN tools for producing reliable QIBs for use in the clinical imaging community. Some of QIBA's development of quantitative diffusion-weighted imaging and dynamic contrast-enhanced QIB profiles has been hampered by the lack of literature for repeatability and reproducibility of the derived QIBs. The available research on this topic is scant and is not in sync with improvements or upgrades in MRI technology over the years. This review focuses on the need for QIBs in oncology applications and emphasizes the importance of the assessment of their reproducibility and repeatability. Level of Evidence: 5 Technical Efficacy Stage: 1 J. Magn. Reson. Imaging 2019;49:e101-e121.
Collapse
Affiliation(s)
- Amita Shukla-Dave
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.,Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Nancy A Obuchowski
- Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio, USA
| | - Thomas L Chenevert
- Department of Radiology, University of Michigan, Ann Arbor, Michigan, USA
| | - Sachin Jambawalikar
- Department of Radiology, Columbia University Irving Medical Center, New York, New York, USA
| | - Lawrence H Schwartz
- Department of Radiology, Columbia University Irving Medical Center, New York, New York, USA
| | - Dariya Malyarenko
- Department of Radiology, University of Michigan, Ann Arbor, Michigan, USA
| | - Wei Huang
- Advanced Imaging Research Center, Oregon Health & Science University, Portland, Oregon, USA
| | - Susan M Noworolski
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, California, USA
| | - Robert J Young
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Mark S Shiroishi
- Division of Neuroradiology, Department of Radiology, University of Southern California, Los Angeles, California, USA
| | - Harrison Kim
- Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Catherine Coolens
- Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Canada
| | | | - Caroline Chung
- Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA
| | - Mark Rosen
- Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Michael Boss
- Applied Physics Division, National Institute of Standards and Technology, Boulder, Colorado, USA
| | - Edward F Jackson
- Departments of Medical Physics, Radiology, and Human Oncology, University of Wisconsin School of Medicine, Madison, Wisconsin, USA
| |
Collapse
|
15
|
deSouza NM. Diffusion-weighted MRI in Multicenter Trials of Breast Cancer: A Useful Measure of Tumor Response? Radiology 2018; 289:628-629. [PMID: 30179102 DOI: 10.1148/radiol.2018181717] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Affiliation(s)
- Nandita M deSouza
- From the MRI Unit, Cancer Research UK Imaging Centre, The Institute of Cancer Research and Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, England
| |
Collapse
|
16
|
Towner RA, Smith N. In Vivo and In Situ Detection of Macromolecular Free Radicals Using Immuno-Spin Trapping and Molecular Magnetic Resonance Imaging. Antioxid Redox Signal 2018; 28:1404-1415. [PMID: 29084431 DOI: 10.1089/ars.2017.7390] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
SIGNIFICANCE In vivo free radical imaging in preclinical models of disease has become a reality. Free radicals have traditionally been characterized by electron spin resonance (ESR) or electron paramagnetic resonance (EPR) spectroscopy coupled with spin trapping. The disadvantage of the ESR/EPR approach is that spin adducts are short-lived due to biological reductive and/or oxidative processes. Immuno-spin trapping (IST) involves the use of an antibody that recognizes macromolecular 5,5-dimethyl-pyrroline-N-oxide (DMPO) spin adducts (anti-DMPO antibody), regardless of the oxidative/reductive state of trapped radical adducts. Recent Advances: The IST approach has been extended to an in vivo application that combines IST with molecular magnetic resonance imaging (mMRI). This combined IST-mMRI approach involves the use of a spin-trapping agent, DMPO, to trap free radicals in disease models, and administration of an mMRI probe, an anti-DMPO probe, which combines an antibody against DMPO-radical adducts and an MRI contrast agent, resulting in targeted free radical adduct detection. CRITICAL ISSUES The combined IST-mMRI approach has been used in several rodent disease models, including diabetes, amyotrophic lateral sclerosis (ALS), gliomas, and septic encephalopathy. The advantage of this approach is that heterogeneous levels of trapped free radicals can be detected directly in vivo and in situ to pin point where free radicals are formed in different tissues. FUTURE DIRECTIONS The approach can also be used to assess therapeutic agents that are either free radical scavengers or generate free radicals. Smaller probe constructs and radical identification approaches are being considered. The focus of this review is on the different applications that have been studied, advantages and limitations, and future directions. Antioxid. Redox Signal. 28, 1404-1415.
Collapse
Affiliation(s)
- Rheal A Towner
- Advanced Magnetic Resonance Center , Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma
| | - Nataliya Smith
- Advanced Magnetic Resonance Center , Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma
| |
Collapse
|
17
|
Bane O, Hectors S, Wagner M, Arlinghaus LL, Aryal M, Cao Y, Chenevert T, Fennessy F, Huang W, Hylton N, Kalpathy-Cramer J, Keenan K, Malyarenko D, Mulkern R, Newitt D, Russek SE, Stupic KF, Tudorica A, Wilmes L, Yankeelov TE, Yen YF, Boss M, Taouli B. Accuracy, repeatability, and interplatform reproducibility of T 1 quantification methods used for DCE-MRI: Results from a multicenter phantom study. Magn Reson Med 2018; 79:2564-2575. [PMID: 28913930 PMCID: PMC5821553 DOI: 10.1002/mrm.26903] [Citation(s) in RCA: 60] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2017] [Revised: 08/14/2017] [Accepted: 08/16/2017] [Indexed: 02/05/2023]
Abstract
PURPOSE To determine the in vitro accuracy, test-retest repeatability, and interplatform reproducibility of T1 quantification protocols used for dynamic contrast-enhanced MRI at 1.5 and 3 T. METHODS A T1 phantom with 14 samples was imaged at eight centers with a common inversion-recovery spin-echo (IR-SE) protocol and a variable flip angle (VFA) protocol using seven flip angles, as well as site-specific protocols (VFA with different flip angles, variable repetition time, proton density, and Look-Locker inversion recovery). Factors influencing the accuracy (deviation from reference NMR T1 measurements) and repeatability were assessed using general linear mixed models. Interplatform reproducibility was assessed using coefficients of variation. RESULTS For the common IR-SE protocol, accuracy (median error across platforms = 1.4-5.5%) was influenced predominantly by T1 sample (P < 10-6 ), whereas test-retest repeatability (median error = 0.2-8.3%) was influenced by the scanner (P < 10-6 ). For the common VFA protocol, accuracy (median error = 5.7-32.2%) was influenced by field strength (P = 0.006), whereas repeatability (median error = 0.7-25.8%) was influenced by the scanner (P < 0.0001). Interplatform reproducibility with the common VFA was lower at 3 T than 1.5 T (P = 0.004), and lower than that of the common IR-SE protocol (coefficient of variation 1.5T: VFA/IR-SE = 11.13%/8.21%, P = 0.028; 3 T: VFA/IR-SE = 22.87%/5.46%, P = 0.001). Among the site-specific protocols, Look-Locker inversion recovery and VFA (2-3 flip angles) protocols showed the best accuracy and repeatability (errors < 15%). CONCLUSIONS The VFA protocols with 2 to 3 flip angles optimized for different applications achieved acceptable balance of extensive spatial coverage, accuracy, and repeatability in T1 quantification (errors < 15%). Further optimization in terms of flip-angle choice for each tissue application, and the use of B1 correction, are needed to improve the robustness of VFA protocols for T1 mapping. Magn Reson Med 79:2564-2575, 2018. © 2017 International Society for Magnetic Resonance in Medicine.
Collapse
Affiliation(s)
- Octavia Bane
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai,Radiology, Icahn School of Medicine at Mount Sinai
| | - Stefanie Hectors
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai,Radiology, Icahn School of Medicine at Mount Sinai
| | - Mathilde Wagner
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai,Radiology, Icahn School of Medicine at Mount Sinai
| | | | | | - Yue Cao
- Radiation Oncology, University of Michigan
| | | | | | - Wei Huang
- Advanced Imaging Research Center, Knight Cancer Institute, Oregon Health and Science University
| | - Nola Hylton
- Radiology, University of California San Francisco
| | | | | | | | | | - David Newitt
- Radiology, University of California San Francisco
| | | | | | | | - Lisa Wilmes
- Radiology, University of California San Francisco
| | | | - Yi-Fei Yen
- Radiology, Massachusetts General Hospital
| | | | - Bachir Taouli
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai,Radiology, Icahn School of Medicine at Mount Sinai
| |
Collapse
|
18
|
Jerome NP, Boult JKR, Orton MR, d'Arcy JA, Nerurkar A, Leach MO, Koh DM, Collins DJ, Robinson SP. Characterisation of fibrosis in chemically-induced rat mammary carcinomas using multi-modal endogenous contrast MRI on a 1.5T clinical platform. Eur Radiol 2018; 28:1642-1653. [PMID: 29038934 PMCID: PMC5834566 DOI: 10.1007/s00330-017-5083-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2017] [Revised: 08/25/2017] [Accepted: 09/14/2017] [Indexed: 12/17/2022]
Abstract
OBJECTIVES To determine the ability of multi-parametric, endogenous contrast MRI to detect and quantify fibrosis in a chemically-induced rat model of mammary carcinoma. METHODS Female Sprague-Dawley rats (n=18) were administered with N-methyl-N-nitrosourea; resulting mammary carcinomas underwent nine-b-value diffusion-weighted (DWI), ultrashort-echo (UTE) and magnetisation transfer (MT) magnetic resonance imaging (MRI) on a clinical 1.5T platform, and associated quantitative MR parameters were calculated. Excised tumours were histologically assessed for degree of necrosis, collagen, hypoxia and microvessel density. Significance level adjusted for multiple comparisons was p=0.0125. RESULTS Significant correlations were found between MT parameters and degree of picrosirius red staining (r > 0.85, p < 0.0002 for ka and δ, r < -0.75, p < 0.001 for T1 and T1s, Pearson), indicating that MT is sensitive to collagen content in mammary carcinoma. Picrosirius red also correlated with the DWI parameter fD* (r=0.801, p=0.0004) and conventional gradient-echo T2* (r=-0.660, p=0.0055). Percentage necrosis correlated moderately with ultrashort/conventional-echo signal ratio (r=0.620, p=0.0105). Pimonidazole adduct (hypoxia) and CD31 (microvessel density) staining did not correlate with any MR parameter assessed. CONCLUSIONS Magnetisation transfer MRI successfully detects collagen content in mammary carcinoma, supporting inclusion of MT imaging to identify fibrosis, a prognostic marker, in clinical breast MRI examinations. KEY POINTS • Magnetisation transfer imaging is sensitive to collagen content in mammary carcinoma. • Magnetisation transfer imaging to detect fibrosis in mammary carcinoma fibrosis is feasible. • IVIM diffusion does not correlate with microvessel density in preclinical mammary carcinoma.
Collapse
Affiliation(s)
- Neil P Jerome
- CR-UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, SM2 5NG, UK
| | - Jessica K R Boult
- CR-UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, SM2 5NG, UK
| | - Matthew R Orton
- CR-UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, SM2 5NG, UK
| | - James A d'Arcy
- CR-UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, SM2 5NG, UK
| | - Ashutosh Nerurkar
- Department of Histopathology, Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK
| | - Martin O Leach
- CR-UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, SM2 5NG, UK
| | - Dow-Mu Koh
- CR-UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, SM2 5NG, UK
- Department of Radiology, Royal Marsden NHS Foundation Trust, London, SM2 5PT, UK
| | - David J Collins
- CR-UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, SM2 5NG, UK
| | - Simon P Robinson
- CR-UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, SM2 5NG, UK.
| |
Collapse
|
19
|
deSouza NM, Winfield JM, Waterton JC, Weller A, Papoutsaki MV, Doran SJ, Collins DJ, Fournier L, Sullivan D, Chenevert T, Jackson A, Boss M, Trattnig S, Liu Y. Implementing diffusion-weighted MRI for body imaging in prospective multicentre trials: current considerations and future perspectives. Eur Radiol 2018; 28:1118-1131. [PMID: 28956113 PMCID: PMC5811587 DOI: 10.1007/s00330-017-4972-z] [Citation(s) in RCA: 41] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2016] [Revised: 05/24/2017] [Accepted: 06/28/2017] [Indexed: 12/18/2022]
Abstract
For body imaging, diffusion-weighted MRI may be used for tumour detection, staging, prognostic information, assessing response and follow-up. Disease detection and staging involve qualitative, subjective assessment of images, whereas for prognosis, progression or response, quantitative evaluation of the apparent diffusion coefficient (ADC) is required. Validation and qualification of ADC in multicentre trials involves examination of i) technical performance to determine biomarker bias and reproducibility and ii) biological performance to interrogate a specific aspect of biology or to forecast outcome. Unfortunately, the variety of acquisition and analysis methodologies employed at different centres make ADC values non-comparable between them. This invalidates implementation in multicentre trials and limits utility of ADC as a biomarker. This article reviews the factors contributing to ADC variability in terms of data acquisition and analysis. Hardware and software considerations are discussed when implementing standardised protocols across multi-vendor platforms together with methods for quality assurance and quality control. Processes of data collection, archiving, curation, analysis, central reading and handling incidental findings are considered in the conduct of multicentre trials. Data protection and good clinical practice are essential prerequisites. Developing international consensus of procedures is critical to successful validation if ADC is to become a useful biomarker in oncology. KEY POINTS • Standardised acquisition/analysis allows quantification of imaging biomarkers in multicentre trials. • Establishing "precision" of the measurement in the multicentre context is essential. • A repository with traceable data of known provenance promotes further research.
Collapse
Affiliation(s)
- N. M. deSouza
- CRUK Cancer Imaging Centre, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Surrey, SM2 5PT UK
| | - J. M. Winfield
- CRUK Cancer Imaging Centre, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Surrey, SM2 5PT UK
| | - J. C. Waterton
- Manchester Academic Health Sciences Institute, University of Manchester, Manchester, UK
| | - A. Weller
- CRUK Cancer Imaging Centre, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Surrey, SM2 5PT UK
| | - M.-V. Papoutsaki
- CRUK Cancer Imaging Centre, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Surrey, SM2 5PT UK
| | - S. J. Doran
- CRUK Cancer Imaging Centre, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Surrey, SM2 5PT UK
| | - D. J. Collins
- CRUK Cancer Imaging Centre, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Surrey, SM2 5PT UK
| | - L. Fournier
- Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Radiology Department, Université Paris Descartes Sorbonne Paris Cité, Paris, France
| | - D. Sullivan
- Duke Comprehensive Cancer Institute, Durham, NC USA
| | - T. Chenevert
- Department of Radiology, University of Michigan Health System, Ann Arbor, MI USA
| | - A. Jackson
- Manchester Academic Health Sciences Institute, University of Manchester, Manchester, UK
| | - M. Boss
- Applied Physics Division, National Institute of Standards and Technology (NIST), Boulder, CO USA
| | - S. Trattnig
- Department of Biomedical Imaging and Image guided Therapy, Medical University of Vienna, 1090 Vienna, Austria
| | - Y. Liu
- European Organisation for Research and Treatment of Cancer, Headquarters, Brussels, Belgium
| |
Collapse
|
20
|
Study of diffusion weighted MRI as a predictive biomarker of response during radiotherapy for high and intermediate risk squamous cell cancer of the oropharynx: The MeRInO study. Clin Transl Radiat Oncol 2017; 2:13-18. [PMID: 29657994 PMCID: PMC5893522 DOI: 10.1016/j.ctro.2016.12.003] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2016] [Revised: 12/06/2016] [Accepted: 12/13/2016] [Indexed: 11/22/2022] Open
Abstract
Introduction and background A significant proportion of patients with intermediate and high risk squamous cell cancer of the oropharynx (OPSCC) continue to relapse locally despite radical chemoradiotherapy (CRT). The toxicity of the current combination of intensified dose per fraction radiotherapy and platinum based chemotherapy limits further uniform intensification. If a predictive biomarker for outcomes from CRT can be identified during treatment then individualised and adaptive treatment strategies may be employed. Methods/design The MeRInO study is a prospective observational imaging study of patients with intermediate and high risk, locally advanced OPSCC receiving radical RT or concurrent CRT Patients undergo diffusion weighted MRI prior to treatment (MRI_1) and during the third week of RT (MRI_2). Apparent diffusion coefficient (ADC) measurements will be made on each scan for previously specified target lesions (primary and lymph nodes) and change in ADC calculated. Patients will be followed up and disease status for each target lesion noted. The primary aim of the MeRInO study is to determine the threshold change in ADC from baseline to week 3 of RT that may identify the sub-group of non-responders during treatment. Discussion The use of DW-MRI as a predictive biomarker during RT for SCC H&N is in its infancy but studies to date have found that response to treatment may indeed be predicted by comparison of DW-MRI carried out before and during treatment. However, previous studies have included all sub-sites and biological sub-types. Establishing ADC thresholds that predict for local failure is an essential step towards using DW-MRI to improve the therapeutic ratio in treating SCC H&N. This would be done most robustly in a specific H&N sub-site and in sub-types with similar biological behaviour. The MeRInO study will help establish these thresholds in OPSCC.
Collapse
|
21
|
Hectors SJ, Wagner M, Corcuera-Solano I, Kang M, Stemmer A, Boss MA, Taouli B. Comparison Between 3-Scan Trace and Diagonal Body Diffusion-Weighted Imaging Acquisitions: A Phantom and Volunteer Study. ACTA ACUST UNITED AC 2016; 2:411-420. [PMID: 28480331 PMCID: PMC5416814 DOI: 10.18383/j.tom.2016.00229] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Diagonal diffusion-weighted imaging (dDWI) uses simultaneous maximized application of 3 orthogonal gradient systems as opposed to sequential acquisition in 3 directions in conventional 3-scan trace DWI (tDWI). Several theoretical advantages of dDWI vs. tDWI include reduced artifacts and increased sharpness. We compared apparent diffusion coefficient (ADC) quantification and image quality between monopolar dDWI and tDWI in a dedicated diffusion phantom (b = 0/500/900/2000 s/mm2) and in the abdomen (b = 50/400/800 s/mm2) and pelvis (b = 50/1000/1600 s/mm2) of 2 male volunteers at 1.5 T and 3.0 T. Phantom estimated signal-to-noise ratio (eSNR) was also measured. Two independent observers assessed the image quality on a 5-point scale. In the phantom, image quality was similar between tDWI and dDWI, with equivalent ADC quantification (mean coefficient of variation [CV] between sequences: 1.4% ± 1.2% at 1.5 T and 0.7% ± 0.7% at 3.0 T). Phantom eSNR was similar for both tDWI and dDWI, except for a significantly lower eSNR for b900 of dDWI at 3.0 T (P = .006). In the volunteers, the CV values between tDWI and dDWI were higher than those in the phantom (CV range: abdominal organs, 1.3%-13.3%; pelvic organs, 0.6%-5.7%). A trend toward significant better image quality for dDWI compared with tDWI was observed for b800 (abdomen) at 3.0 T and for b1000 and b1600 (pelvis) at 1.5 T (P = .063 to .066). Our data suggest that dDWI may provide better image quality than tDWI without affecting ADC quantification, needing confirmation in a future clinical study.
Collapse
Affiliation(s)
- Stefanie J Hectors
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York.,Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Mathilde Wagner
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York.,Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Idoia Corcuera-Solano
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York.,Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Martin Kang
- Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Alto Stemmer
- Siemens AG, Medical Solutions, Magnetic Resonance, Erlangen, Germany
| | - Michael A Boss
- Applied Physics Division, National Institute of Standards and Technology, Boulder, Colorado
| | - Bachir Taouli
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York.,Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, New York
| |
Collapse
|